Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.67 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783124 | 1.00 | CTNNB1 (0.67) | CTNNB1TCF7L2AKR1B1ALDH1A1KMT2A | |
| SCHEMBL20534584 | 0.90 | MAOA (0.69) | AKR1B1CA9MAOAMAOBCISD1 | |
| SCHEMBL17319530 | 0.90 | MAOA (0.69) | AKR1B1CA9MAOAMAOBCISD1 | |
| SCHEMBL20534555 | 0.89 | AKR1B1 (0.61) | AKR1B1CA9MAOAMAOBCISD1 | |
| SCHEMBL20534556 | 0.89 | AKR1B1 (0.61) | AKR1B1CA9MAOAMAOBCISD1 | |
| SCHEMBL21773419 | 0.89 | AKR1B1 (0.61) | AKR1B1CA9MAOAMAOBCISD1 | |
| SCHEMBL21783134 | 0.87 | PPARG (0.64) | CTNNB1TCF7L2ALDH1A1KMT2A | |
| SCHEMBL20534482 | 0.87 | PPARG (0.64) | CTNNB1TCF7L2ALDH1A1KMT2A | |
| SCHEMBL20534483 | 0.87 | PPARG (0.64) | CTNNB1TCF7L2ALDH1A1KMT2A | |
| SCHEMBL8185563 | 0.83 | CA9 (0.61) | AKR1B1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | LA TROBE UNIVERSITY (AU) | 2020-03-05 | — | — | US | disclosed |
| EP-3609494-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | La Trobe University (AU) | 2020-02-19 | — | — | EP | disclosed |
| CN-110621315-A | Heterocyclic inhibitors of lysine biosynthesis via the diaminopimelic acid pathway | 拉筹伯大学 | 2019-12-27 | — | — | CN | disclosed |
| WO-2018187845-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | LA TROBE UNIVERSITY (AU) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | DDC, ODC1, DDT | CTNNB1 4404/4885TCF7L2 3142/4885AKR1B1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.